Indivior PLC (LON:INDV – Get Free Report) shares were down 15.7% during mid-day trading on Thursday . The company traded as low as GBX 548.71 ($6.95) and last traded at GBX 732 ($9.28). Approximately 1,888,371 shares traded hands during trading, an increase of 166% from the average daily volume of 709,477 shares. The stock had previously closed at GBX 868 ($11.00).
Analysts Set New Price Targets
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 1,800 ($22.81) target price on shares of Indivior in a research report on Tuesday, December 17th.
View Our Latest Stock Report on INDV
Indivior Stock Down 15.7 %
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- Investing in Construction Stocks
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Why Are These Companies Considered Blue Chips?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Investing in the High PE Growth Stocks
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.